Bookmark and Share

Compound Summary for: CID 115237


Also known as: Paliperidone; Invega; 9-Hydroxyrisperidone; 144598-75-4; 9-OH-risperidone; Invega Sustenna; Paliperidone [INN]; PALLIPERIDONE; RO-76477
Molecular Formula: C23H27FN4O3   Molecular Weight: 426.483883   InChIKey: PMXMIIMHBWHSKN-UHFFFAOYSA-N
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.   From: DrugBank
Show subcontent titlesTable of Contents
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Biomedical Effects and Toxicity
Safety and Handling
Environmental Fate and Exposure Potential
Exposure Standards and Regulations
Monitoring and Analysis Methods
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties
_ _